| 前收盘价格 | 2.90 |
| 收盘价格 | 2.93 |
| 成交量 | 56,429 |
| 平均成交量 (3个月) | 55,721 |
| 市值 | 1,061,909,888 |
| 预期市盈率 (P/E Forward) | 59.88 |
| 价格/销量 (P/S) | 1.29 |
| 股市价格/股市净资产 (P/B) | 1.22 |
| 52周波幅 | |
| 利润日期 | 5 Nov 2025 |
| 营业毛利率 | -26.26% |
| 营业利益率 (TTM) | -9.91% |
| 稀释每股收益 (EPS TTM) | -0.690 |
| 季度收入增长率 (YOY) | -4.20% |
| 总债务/股东权益 (D/E MRQ) | 52.48% |
| 流动比率 (MRQ) | 2.03 |
| 营业现金流 (OCF TTM) | 34.59 M |
| 杠杆自由现金流 (LFCF TTM) | -90.11 M |
| 资产报酬率 (ROA TTM) | -2.42% |
| 股东权益报酬率 (ROE TTM) | -20.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Evotec SE | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -4.0 |
| 平均 | 0.50 |
|
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Core |
| 机构持股比例 | 2.56% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Pitcairn Co | 30 Sep 2025 | 161,769 |
| Snowden Capital Advisors Llc | 30 Sep 2025 | 29,053 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合